Nurix Therapeutics, Inc (NRIX)

Etorro trading 970x250
Nurix Therapeutics, Inc (NRIX) Logo

About Nurix Therapeutics, Inc

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton’s tyrosine kinase (BTK) degrader with immunomodulatory drug (IMiD) activity for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader without IMiD activity for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; DeTIL-0255 for tumor infiltrating lymphocytes therapy; KINASE-CTM3 to treat T cell malignancies and autoimmune diseases; and LIGASE-INH2 for immuno-oncology. In addition, the company develops programs, such as COVID-CTM1, COVID-CTM2, and COVID-CTM3 that are designed for protein degradation to SARs CoV2 targets. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California. Address: 1700 Owens Street, San Francisco, CA, United States, 94158

Nurix Therapeutics, Inc News and around…

Latest news about Nurix Therapeutics, Inc (NRIX) common stock and company :

Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Tops Revenue Estimates
14 Oct, 2021 Yahoo! Finance

Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 1.52% and 17.49%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock?

Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
14 Oct, 2021 Yahoo! Finance

Initiated Phase 1 trial of lead CBL-B E3 ligase inhibitor program NX-1607 in patients with cancer Expanded Board of Directors with experienced business leaders Strong financial position with $465.4 million as of August 31, 2021 SAN FRANCISCO, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the third quarter ended August 31, 2021 and provided a corporate update

Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
14 Oct, 2021 FinancialContent

Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX:REI) was changed from Neutral to Buy. For the second ...

Nurix Therapeutics Expands its Board of Directors with the Addition of Two Industry Leaders
30 Sep, 2021 FinancialContent
Stock Upgrades: Nurix Therapeutics Shows Rising Relative Strength
05 Aug, 2021 FinancialContent

Nurix Therapeutics sees its Relative Strength Rating hit the 80-plus level.

Return on Capital Employed Insights for Nurix Therapeutics
29 Jul, 2021 FinancialContent

After pulling data from Benzinga Pro it seems like during Q2, Nurix Therapeutics (NASDAQ:NRIX) brought in sales totaling $7.09 million. ...

Is Nurix Therapeutics, Inc. (NRIX) A Good Stock To Buy?
27 Jul, 2021 Yahoo! Finance

In this article we are going to use hedge fund sentiment as a tool and determine whether Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a good investment right now. We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, […]

The Nurix Therapeutics (NASDAQ:NRIX) Share Price Is Up 62% And Shareholders Are Holding On
26 Jul, 2021 Yahoo! Finance

These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But you can...

First Week of September 17th Options Trading For Nurix Therapeutics (NRIX)
20 Jul, 2021 FinancialContent

Investors in Nurix Therapeutics Inc (NRIX) saw new options become available this week, for the September 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NRIX options chain for the new September 17th contracts and identified one put and one call contract of particular interest.

Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
13 Jul, 2021 FinancialContent
Sum Up The Pieces: LABU Could Be Worth $109
08 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Daily S&P Biotech Bull 3X Shares ETF (LABU), we found that the implied analyst target price for the ETF based upon its underlying holdings is $109.21 per unit.

Nurix Therapeutics Announces Appointment of Stefani A. Wolff as Chief Operating Officer and Executive Vice President, Product Development
21 Jun, 2021 FinancialContent
Nurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reduction of Inflammation in a Model of Autoimmune Disease
02 Jun, 2021 FinancialContent
Nurix Therapeutics Appoints Industry Leader Clay Siegall, Ph.D., to its Board of Directors
01 Jun, 2021 FinancialContent
Nurix Therapeutics Announces Upcoming Presentation of NX-5948 Preclinical Data at the EULAR 2021 Virtual Congress
21 May, 2021 FinancialContent

NX-5948, a potent selective degrader of BTK, significantly reduces inflammation in a model of autoimmune disease

Nurix Therapeutics to Participate in Upcoming Investor Conferences
11 May, 2021 FinancialContent
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Analysts Just Cut Their EPS Forecasts Substantially
18 Apr, 2021 Yahoo! Finance

The analysts covering Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) delivered a dose of negativity to shareholders today, by...

4 Top Biotech Stocks To Watch In The Stock Market Today
15 Apr, 2021 FinancialContent
48 Biggest Movers From Yesterday
15 Apr, 2021 FinancialContent

Gainers Alkami Technology, Inc. (NASDAQ: ALKT) shares surged 43.3% to settle at $43.00 on Wednesday after the company priced its ...

Mid-Afternoon Market Update: Dow Gains Over 100 Points; Bed Bath & Beyond Shares Plummet
14 Apr, 2021 FinancialContent

Toward the end of trading Wednesday, the Dow traded up 0.33% to 33,787.64 while the NASDAQ fell 0.62% to 13,908.97. The S&P also ...

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2021
14 Apr, 2021 FinancialContent

Upgrades For Cardlytics Inc (NASDAQ:CDLX), Craig-Hallum upgraded the previous rating of Hold to Buy. For the fourth ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
14 Apr, 2021 FinancialContent

Gainers Nurix Therapeutics (NASDAQ:NRIX) stock moved upwards by 18.37% to $31.44 during Wednesday's regular session. ...

Mid-Day Market Update: Crude Oil Rises 4.5%; Grupo Televisa Shares Spike Higher
14 Apr, 2021 FinancialContent

Midway through trading Wednesday, the Dow traded up 0.61% to 33,881.54 while the NASDAQ fell 0.24% to 13,962.31. The S&P also rose, ...

30 Stocks Moving In Wednesday's Mid-Day Session
14 Apr, 2021 FinancialContent

Gainers Discovery, Inc. (NASDAQ: DISCB) shares climbed 37.3% to $102.99. Grupo Televisa, S.A.B. (NYSE: TV) shares climbed 22.4% ...

Analyzing The Price Action In Nurix Therapeutics Stock Today
14 Apr, 2021 FinancialContent

Nurix Therapeutics's Stock Price And Volume Action Nurix Therapeutics's (NASDAQ:NRIX) stock has been rising Wednesday, up ...

Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
13 Apr, 2021 FinancialContent
Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
07 Apr, 2021 FinancialContent
Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
07 Apr, 2021 Yahoo! Finance

SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s chief executive officer, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14th, 2021 at 11:45 a.m. ET. The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. An archived copy of the webcast will be available on the Nurix website for approximately 30 days after the event. About Nurix Therapeutics, Inc. Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurix.com. Contacts: Investors:Media:Jason Kantor, Ph.D.Elizabeth Wolffe, Ph.D.Nurix Therapeutics, Inc.Wheelhouse Life Science Advisorsjkantor@nurixtx.comlwolffe@wheelhouselsa.com

54 Biggest Movers From Yesterday
06 Apr, 2021 FinancialContent

Gainers Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares climbed 60.2% to close at $5.64 on Monday after the company announced the ...

50 Biggest Movers From Friday
22 Mar, 2021 FinancialContent

Gainers Clovis Oncology, Inc. (NASDAQ: CLVS) shares climbed 47.7% to close at $7.86 on Friday after the company announced its ...

Nurix Therapeutics, Inc (NRIX) is a NASDAQ Common Stock listed in , ,

970x250